Ganguli M, Chandra V, Kamboh M I, Johnston J M, Dodge H H, Thelma B K, Juyal R C, Pandav R, Belle S H, DeKosky S T
Western Psychiatric Institute and Clinic, 3811 O'Hara St, Pittsburgh, PA 15213-2593, USA.
Arch Neurol. 2000 Jun;57(6):824-30. doi: 10.1001/archneur.57.6.824.
The APOE*E4 allele of the gene for apolipoprotein E (APOE) has been reported as a risk factor for Alzheimer disease (AD) to varying degrees in different ethnic groups.
To compare APOE*E4-AD epidemiological associations in India and the United States in a cross-national epidemiological study.
Case-control design within 2 cohort studies, using standardized cognitive screening and clinical evaluation to identify AD and other dementias and polymerase chain reaction to identify APOE genotyping.
Rural community samples, aged 55 years or older (n=4450) in Ballabgarh, India, and 70 years or older (n=886) in the Monongahela Valley region of southwestern Pennsylvania.
Criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association for probable and possible AD and Clinical Dementia Rating (CDR) scale for dementia staging.
Frequency of APOEE4 was significantly lower (P<.001) in Ballabgarh vs the Monongahela Valley (0.07 vs 0.11). Frequency of probable or possible AD, with CDR of at least 1.0, in the Indian vs US samples, was as follows: aged 55 to 69 years, 0.1% (Indian sample only); aged 70 to 79 years, 0.7% vs 3.1%; aged 80 years or older, 4.0% vs 15.7%. Among those aged 70 years or older, adjusted odds ratios (95% confidence interval) for AD among carriers of APOEE4 vs noncarriers were 3.4 (1.2-9.3) and 2.3 (1.3-4.0) in the Indian and US samples, respectively, and not significantly different between cohorts (P=. 20).
This first report of APOEE4 and AD from the Indian subcontinent shows very low prevalence of AD in Ballabgarh, India, but association of APOEE4 with AD at similar strength in Indian and US samples. Arch Neurol. 2000.
载脂蛋白E（APOE）基因的APOE*E4等位基因在不同种族中被报道为阿尔茨海默病（AD）的不同程度的危险因素。
在一项跨国流行病学研究中比较印度和美国APOE*E4与AD的流行病学关联。
在2项队列研究中采用病例对照设计，使用标准化认知筛查和临床评估来识别AD和其他痴呆症，并使用聚合酶链反应来识别APOE基因分型。
印度巴拉加尔55岁及以上的农村社区样本（n = 4450）以及宾夕法尼亚州西南部莫农加希拉谷地区70岁及以上的样本（n = 886）。
美国国立神经疾病和中风研究所 - 阿尔茨海默病及相关疾病协会关于可能和疑似AD的标准以及用于痴呆分期的临床痴呆评定量表（CDR）。
巴拉加尔的APOEE4频率显著低于莫农加希拉谷（P <.001）（0.07对0.11）。印度和美国样本中，CDR至少为1.0的可能或疑似AD的频率如下：55至69岁，0.1%（仅印度样本）；70至79岁，0.7%对3.1%；80岁及以上，4.0%对15.7%。在70岁及以上人群中，APOEE4携带者与非携带者相比，AD的校正比值比（95%置信区间）在印度和美国样本中分别为3.4（1.2 - 9.3）和2.3（1.3 - 4.0），队列间无显著差异（P =.20）。
这份来自印度次大陆的关于APOEE4与AD的首次报告显示，印度巴拉加尔的AD患病率非常低，但APOEE4与AD在印度和美国样本中的关联强度相似。《神经病学档案》。2000年。
